



Freedom of Information Team  
De La Court House  
Queen Alexandra Hospital  
Southwick Hill Road  
Portsmouth  
Hampshire  
PO6 3LY

Date: 17/05/2022

Ref: 21-22 586

Dear Sir or Madam,

**Re: Freedom of Information request**

Firstly, please accept our sincere apologies for the delay in responding to you.

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 18/02/2022. Please see responses to your requests below.

**1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

- **Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent**
- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Abemaciclib + Fulvestrant**
- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent**
- **Atezolizumab +Nab-paclitaxel/Paclitaxel**
- **Capecitabine as a single agent**
- **Carboplatin or Cisplatin as a single agent**
- **Eribulin as a single agent or in combination**
- **Everolimus + Exemestane**
- **Fulvestrant as a single agent**
- **Lapatinib**
- **Neratinib**
- **Parp Inhibitors (Olaparib/Talazoparib)**
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Palbociclib + Fulvestrant**
- **Pembrolizumab**
- **Pertuzumab + Trastuzumab + Docetaxel**
- **Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Ribociclib + Fulvestrant**
- **Sacituzumab Govitecan**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent**
- **Trastuzumab as a single agent or in combination**
- **Trastuzumab emtansine**
- **Transtuzumab deruxtecan**
- **Vinorelbine as a single agent**

- **Any other active systemic anti-cancer therapy**

The Trust is only able to provide information in relation to drug dispensing, we do not record diagnoses on our clinical systems so therefore we are unable to link the type of drug to diagnosis.

To extract this information, we would have to search through a significant amount of patient records. It is estimated that to attempt to retrieve all the information you require would take a considerable amount of retrieval time, which would exceed 18 hours. This would exceed the appropriate limit for dealing with a Freedom of Information Request, in terms of costs and therefore Section 12(1) of the Freedom of Information Act 2000 applies.

**2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent?**

Please see answer to question 1.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on [Information.Governance@porthosp.nhs.uk](mailto:Information.Governance@porthosp.nhs.uk) or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team